Introduction
The landscape of oncological practice has substantially changed with the introduction of immune checkpoint inhibitors that target inhibitory receptors on the surface of CD8 + T cells (1) . In particular, blocking of the inhibitory receptor programmed death 1 (PD-1) or its ligand PD-L1 has been shown to induce durable responses across many different cancer types, including non-small cell lung cancer (NSCLC), melanoma, squamous carcinoma of the head and neck, kidney cancer, and ovarian cancer (1, 2) . However, most patients have primary resistance to therapeutic PD-1 or PD-L1 blockade or develop secondary resistance (2) . Thus, identification of additional pathways mediating suppression of tumor-specific T cells is clearly needed to increase therapeutic efficacy of PD-1-or PD-L1-targeting strategies.
Pattern recognition receptors (PRRs), such as Toll-like receptors or nucleotide-binding oligomerization domain-like (NODlike) receptors, detect pathogens or danger signals, and engagement of these PRRs by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) activates the respective immune cells (3) (4) (5) (6) . Receptors that bind to PAMPs and DAMPs have also been implicated in cancer progression and anticancer immunity (6, 7) . In addition to these well-described pathways, sialoglycans have been shown to serve as a self-associated molecular patterns (SAMPs) by binding to CD33-related sialic acid-binding immunoglobulin-like lectins (CD33rSiglecs) (8, 9) , a family of receptors on immune cells containing intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM) (10) (11) (12) (13) . Unlike the conserved Siglecs (Siglec-1, Siglec-2, Siglec-4, and Siglec-15), CD33rSiglecs, including Siglec-3 (CD33), Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, Siglec-10, Siglec-11, Siglec-14, and Siglec-16, have evolved rapidly due to multiple selection forces, including evolutionary pressure by pathogens that can mimic sialoglycan-SAMPs (Sia-SAMPs) and bind to inhibitory CD33rSiglecs to escape innate immune control (14) (15) (16) (17) (18) . The different Siglecs have different binding preferences for sialoglycan ligands (9) . While Siglec-8 has a more defined spectrum of ligands, which include 6′-sulfo-sialyl Lewis x (19, 20) , Siglec-9 has a much broader binding spectrum of sialylated ligands (9, 21) . Siglec-9 is therefore a typical PRR for Sia-SAMPs.
Recent evidence suggests that the upregulation of Sia-SAMPs can facilitate evasion of immune control during cancer progression First-generation immune checkpoint inhibitors, including anti-CTLA-4 and anti-programmed death 1 (anti-PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid-binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9-expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anticancer immunity. T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. Our data identify the sialoglycan-SAMP/Siglec pathway as a potential target for improving T cell activation for immunotherapy.
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells Michal A. Stanczak, 1,2 Shoib S. Siddiqui, 3 Marcel P. Trefny, 1,2 Daniela S. Thommen, 1,2 Kayluz Frias Boligan, 4 Stephan von Gunten,
There was a significant increase of Sia-SAMPs (Siglec-7 and Siglec-9 ligands) in lung carcinomas compared with healthy lung tissue as well as in acute and chronic inflammatory diseases, as assessed with Siglec-Fc proteins ( Figure 1, H and I ). Ligands were strongly present on cytokeratin-positive cells, suggesting they were in a trans position, and a trend toward an increase in ligands at higher stages was observed (Supplemental Figure 1L) . As Siglec-9 was the most prominent and consistent inhibitory CD33rSiglec upregulated on TILs across different patients, we focused our further analysis on Siglec-9.
Characterization of Siglec-9-expressing intratumoral CD8 + T cells. We aimed to further characterize the Sig9 + CD8
+ TILs in samples from NSCLC patients by multicolor flow cytometry. Sig9
+ TILs coexpressed several other inhibitory receptors, including PD-1 in particular and also TIM-3 and LAG-3 ( Figure 2 
CD8
+ TILs were SPP1 (osteopontin), Ki67, and KLF4 ( Figure 2F ). We also looked for the expression of genes involved in the generation of Sia-SAMPs. Expression of the rate-limiting enzyme for sialic acid biosynthesis, UDP-N-acetylglucosamine-2-epimerase (GNE), was higher in Sig9 + CD8
+ TILs than in Sig9 -CD8 + TILs (Supplemental Figure 2L ). Consequently, an upregulation of sialoglycans, as shown by increased staining with Sambucus nigra lectin (SNA) (Supplemental Figure 2M) , and an upregulation of cis ligands on TILs, as shown by increased staining with Siglec-9-Fc protein, occurred (Supplemental Figure 2N ). Protein levels of osteopontin (SPP1) ( Supplemental Figure 2 , O and P) and Ki-67 (Supplemental Figure 2Q ) were also significantly higher in Sig9 + CD8
+ TILs than in Sig9 -CD8 + TILs (Supplemental Figure 3 shows the gating strategy for sorting of primary T cells from tumor samples).
Sig9 + TILs are a distinct subset within the CD8 + T cell population. We further tested to determine whether Siglecs are upregulated by activation of T cells. While Siglec-5 expression increased significantly on polyclonally activated CD8 + T cells from healthy donors, Siglec-9 was only slightly upregulated and Siglec-7 expression was unchanged (Supplemental Figure 4A) . Antigen-specific stimulation of T cell clones with reactivity against peptides from influenza antigens, CMV antigens, and melanA led to a slight upregulation of Siglec-9 (Supplemental Figure 4B ). Sig9
+ TILs from NSCLC samples activated with anti-CD3/anti-CD28 antibodies expressed significantly higher surface levels of CD25 ( Figure 3A ), CD69 ( Figure 3B ), and the newly identified activation marker Siglec-5 (Supplemental Figure 4C ) compared with similarly actiby engaging inhibitory CD33rSiglecs, such as Siglec-7 and Siglec-9 (21) (22) (23) (24) (25) (26) . Engagement of Siglec-7 and Siglec-9 inhibits NK cellmediated tumor cell killing in vitro (22, 23) . Siglec-9 and its murine functional paralog Siglec-E have also been implicated in myeloid cell-mediated cancer progression (21, 24) . Binding of the cancerassociated sialylated glycoform of MUC1 to Siglec-9 on macrophages can induce a tumor-associated macrophage (TAM) phenotype that can promote cancer progression and immune evasion (25) .
In chronic infections and cancer, expression of checkpoint molecules, including PD-1, CTLA-4, TIM-3, and LAG-3, is observed on T cells and is associated with a state of T cell dysfunction termed T cell exhaustion (27) . Chronic infections, such as HIV, have also been shown to upregulate inhibitory CD33r-Siglecs on peripheral CD4 + T cells, which suggests that inhibitory Siglec receptors might be involved in T cell immunoregulation (28) . In contrast, previous analyses have found very low expression of CD33rSiglecs on peripheral T cells of healthy humans (29) and mice (30) . We therefore sought to characterize Siglec expression on tumor-infiltrating T cells and to test the functional role of Siglecs as new potential immune checkpoints that are regulated by glycans within the tumor microenvironment.
Results

Siglec-9 is upregulated on tumor-infiltrating T cells.
We analyzed the expression of inhibitory CD33rSiglecs on immune cells in primary NSCLC samples (Supplemental Figure 1A ; supplemental material available online with this article; https://doi. org/10.1172/JCI120612DS1). As previously described, CD33r-Siglecs, including Siglec-7 and Siglec-9, were expressed on NK cells and Siglec-9 was also expressed on myeloid cells (Supplemental Figure 1B ). Several inhibitory CD33rSiglecs, including Siglec-3 (CD33), Siglec-5, Siglec-7, Siglec-10, and Siglec-9, were expressed on a significant proportion of tumor-infiltrating lymphocytes (TILs), including CD4 + and CD8 + T cells (Figure 1 , A-G, and Supplemental Figure 1 , C-F). Siglec-9 was the most prominently and consistently expressed CD33rSiglec on TILs across patients ( Figure 1G ). Lower levels of Siglec-9 were observed on peripheral blood T cells from healthy donors (Figure 1 , A-C) or in spleens from patients undergoing splenectomy for nonmalignant disease (Supplemental Figure 1G ). There were a few healthy donors that had a larger population of Siglec-9-expressing CD8 + T cells ( Figure 1C) . In order to further understand the heterogeneity of Siglec-9 expression, we further stained for Siglec-9 in an additional and better-characterized population of 49 healthy donors (Supplemental Figure 1H) . The distribution of Siglec-9 on CD8 + T cells was similar in both cohorts, and no correlation with age could be seen (Supplemental Figure 1I) Figure 1J ). Immunostaining of intratumoral leukocytes showed that Siglec-9 was typically expressed on small lymphocytes and macrophages ( Figure 1E ). Double staining showed that Siglec-9-positive TILs in NSCLC samples also expressed CD3 ( Figure 1F ). We also found an upregulation of Siglec-9 on colorectal cancer (CRC) and epithelial ovarian cancer (EOC) TILs or pleural effusions (Supplemental Figure 1K ).
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jci.org Volume 128 Number 11 November 2018 To test the effect of Siglec-9 blockade on T cell activation in vitro, we used a Siglec-9 antibody and the previously described staphylococcal enterotoxin B (SEB) test (32) . Two full IgG Siglec-9 antibodies (191240 and E10-286) inhibited T cell activation and therefore were agonistic (Supplemental Figure 7 , G and H). Moreover, Siglec-9 antibodies led to a dose-dependent inhibition of T cell activation tested by upregulation of the activation markers CD25 ( Figure 4J ) and CD69 (Supplemental Figure 7I) . Addition of the Siglec-9 antibody (clone 191240) inhibited IL-2 production and CD69 expression on the surface of TILs upon SEB stimulation of + TILs with a distinct, higher functionality (31); this subpopulation was associated with an increased expression of CD5 and a lower expression of CD38 and CD101 (31) . We therefore stained for these markers and found an enrichment of CD5 and Ki67 expression ( + cells are a distinct subpopulation of tumor-specific CD8 + TILs. Sia-SAMP/Siglec-9 interaction is a target for improving T cell activation. Next, we wanted to explore the functional implication of Siglec expression on T cells. We used the high-affinity CD33rSiglec ligand LGALS3BP, which is upregulated in NSCLC (24) . LGALS3BP inhibited CD8 + T cell activation in a sialic aciddependent fashion ( Figure 4A, Supplemental Figure 7 , A and B). We further generated cell lines that expressed lower surface levels of Sia-SAMPs by knocking out GNE. GNE-deficient A549 lung adenocarcinoma cells showed lower binding to Siglec-9 compared Figure 8J) . In order to analyze the role of adaptive immunity, we repeated the experiment in primary NSCLC samples ( Figure 4 , K and L). We hypothesized that bivalent binding and subsequent dimerization of Siglec-9 might be responsible for the agonistic effect on Siglec-9 by the clone 191240. Indeed, monovalent carbohydrate-recognition domainblocking (CRD-blocking) Fab fragments from clone 191240 (Supplemental Figure 7J ) significantly increased IL-2 ( Figure 4K ), but not CD69 ( Figure 4L ), production upon SEB stimulation. These findings demonstrate that T cell activation in NSCLC tumors can be increased by targeting Sia-SAMPs/Siglec-9 interactions.
Siglec-E is expressed on TILs in mice.
We further investigated whether the murine functionally equivalent paralog (Siglec-E) was upregulated on TILs in mouse models. We found a significant upregulation of Siglec-E on murine CD8 + TILs when compared with splenocytes from control mice and tumor-bearing mice in the MC38 subcutaneous tumor model ( Figure 5A ) and other models (LLC, B16, and EMT6 subcutaneous tumor models; Supplemental Figure 8A ). While other inhibitory CD33rSiglecs, including Siglec-F and Siglec-G, were also upregulated on the surface of murine TILs, Siglec-E was the most prominently upregulated inhibitory Siglec tested (Supplemental Figure 8B) . We further analyzed the phenotype of SigE Figure 8K) . From these findings, we concluded the sialylation directly affects tumor growth and also the antitumor immune response by enhancing the adaptive immune response to cancer (Supplemental Figure 9 shows the gating strategy for determining Siglec-E expression on tumor-infiltrating T cells).
Expression of Siglec receptors on T cells directly modulate antitumor immunity.
To further investigate the role of Sia-SAMPs and their interactions with CD33rSiglecs, we used a human Siglec-9 transgenic mouse (HS9) that allows selective expression of Siglec-9 in cells producing Cre recombinase (21) . Previous analysis demonstrated that human Siglec-9 binds to ligands on murine tumor cells (21) . HS9 mice were crossed with CD4-Cre mice to express human Siglec-9 in T cells. These mice expressed Siglec-9 in both CD4 + and CD8 + T cells (Supplemental Figure 10A) . The growth of syngeneic MC38 tumor cells was accelerated in mice expressing Siglec-9 in T cells, and the tumors grew larger compared with those in littermate control mice ( Figure 6A ). This finding supports the hypothesis that inhibitory Siglecs on T cells can mediate immune evasion. We also used the recently developed Siglec-E16 (SigE16) transgenic mice (18) . These mice express a chimeric Siglec receptor with the extracellular domain of Siglec-E and the transmembrane and intracellular domain of the activating human Siglec-16 receptor under the Siglec-E promoter (18) . No major differences were observed between the frequency of naive and memory T cells in different genetic animal models (Supplemental Figure 10B ). Siglec-E expression in WT and SigE16 mice was similar (Supplemental Figure 10C) . Compared with those in WT littermate control mice, subcutaneous syngeneic MC38 tumors grew more slowly and remained smaller in homozygous + TILs from NSCLC patients upon incubation with SEB in the presence of antibodies or Fab fragments (n = 5). Statistical analyses in this figure were performed by 1-way ANOVA. Data are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. jci.org Volume 128 Number 11 November 2018
SigE16 mice ( Figure 6B ). MC38 tumors had an increased induction of antitumor antibodies (Supplemental Figure 10D) . Depletion experiments demonstrated the dependence of the effect on both CD4 + and CD8 + T cells and directly showed that the genetic reversal of an inhibitory into an activating Siglec receptor can also influence T cell activation ( Figure 6, C and D) . We also used an adoptive transfer model to study the role of Siglec-E on T cells. We transferred OT-I T cells expressing either WT Siglec-E or activating SigE16 into WT mice with OVA-expressing MC38-OVA tumors and measured the growth of tumors. MC38-OVA tumors in mice transferred with OT-I from SigE16 mice had significantly reduced tumor growth ( Figure 6E ). In addition, OT-I T cells expressing SigE16 had increased proliferation (Supplemental Figure 10E) . In addition, a trend toward increased infiltration was also seen in mice adoptively transferred with SigE16-expressing OT-I T cells (Supplemental Figure 10F) . To determine the effect of sialoglycans in trans position on the growth difference in SigE16 mice, we used MC38 WT and GNE-KO cells. The previous growth difference could no longer be seen in the SigE16 background (Supplemental Figure 10G ). This finding suggests that the effect seen in SigE16 mice is mediated by interactions of trans ligands with activating SigE16 receptor.
Sig9 + TILs and Siglec-9 polymorphisms are associated with clinical end points. We further analyzed the correlation of Siglec expression on T cells with clinical parameters. Patients with a high frequency of Sig9 + TILs (>30% of CD8 + T cells) had significantly worse overall survival ( Figure 6F ). The significance was slightly reduced in a multivariate analysis taking age and also stage into account (P = 0.0668 with a hazard ratio of 14.6 by a Cox proportional hazard regression analysis). Recently, polymorphisms of Siglec-9 were associated with pulmonary diseases (33) . We studied to determine whether the risk of developing lung cancer was associated with the rs2075803 and rs2258983 polymorphisms in the TRICL4 cohort (34) . The risk of developing squamous cell lung cancer was significantly reduced in the presence of these polymorphisms (Table 1) . We also examined the polymorphisms rs2075803 and rs2258983 in 3,795 cases of CRC and 3,044 controls to estimate the relative risk of developing CRC. Individuals How Siglec-9 is upregulated on TILs and how Siglecs are regulated in T cells, including intracellular signaling, remain unclear. We observed only a slight upregulation of Siglec-9 upon polyclonal and antigen-specific stimulation of healthy T cells. Other immune checkpoint receptors are upregulated through repetitive antigenic stimulation or the tumor microenvironment, including inhibitory cytokines (27) . We have seen a similar effect in several mouse models, indicating that the mechanism for Siglec upregulation in T cells appears to be conserved across species, even though Siglec receptors have diverged quite a lot between mice and humans. We observed a heterogeneity of the frequency in Sig9 + CD8 + T cells in the peripheral blood of healthy donors and an inverse correlation with the frequency of naive CD8 + T cells. This finding suggests that healthy individuals with more circulating peripheral memory T cells also have a higher number of Sig9 + CD8 + T cells. Until now, mainly Siglec-9-expressing NK cells and myelomonocytic cells have been associated with immune modulation in cancer. Myeloid cells were more reactive in a mouse model of Siglec-E deficiency, and increased immunosurveillance was observed in these mice (21) . Engagement of Siglec-9 on monocytes/macrophages by a cancer-associated, sialylated glycoform of MUC1 showed polarization toward immune-suppressive TAMs with upregulation of PD-L1 (25) . Two analyses examined the function of inhibitory Siglec-7 and Siglec-9 in NK cell-mediated tumor cell killing (22, 23) . Other immune receptors, including PD-1, are also expressed who were homozygous A for the rs2075803 SNP and homozygous C for the rs2258983 SNP had a significantly reduced risk of developing CRC (Supplemental Table 1 ).
Discussion
Recent studies have shown that inhibitory CD33rSiglecs can modulate the interactions of immune cells with tumor cells by sialic acid-dependent mechanisms (21-23, 25, 26) , raising the possibility that these Siglecs could be used for therapeutic checkpoint inhibition, analogous to the remarkable recent therapeutics directed against PD-1 or CTLA-4 (2). We and others have shown that T cells from healthy humans express low levels of CD33-related Siglecs (29, 35) . However, we show here that expression of the inhibitory Siglec-9 is clearly increased on CD4 + and CD8 + TILs compared with peripheral T cells from healthy donors. We also observed the presence of Siglec ligands in both cis and trans positions. In addition, we confirmed previous observations that have shown a small population of peripheral T cells with Siglec-7 and Siglec-9 expression (35) . Properly glycosylated CD52 has previously been identified as a ligand for Siglec-10 on human T cells (36) . Furthermore, inhibitory mouse Siglec-G (often referred to as the murine paralog of human Siglec-10) was found to inhibit DAMP-associated T cell activation (37) . These investigations demonstrate that Siglecs can dampen T cell responses in the context of general inflammation. + T cells. Differences were analyzed by Wilcoxon's test. A multivariate analysis of the 2 groups for age and stage showed slightly reduced significance, with a P value of 0.0669 (multivariate, univariate analysis P = 0.0097) and a hazard ratio of 14.6.
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to the activation of Siglec-9 signaling by dimerization. In contrast, the use of monovalent Fab fragments of the antibody clone 191240, which inhibits Sia-SAMP/Siglec-9 interactions by hampering ligand binding to the CRD, led to increased T cell activation. This result suggests that the Sia-SAMP/Siglec-9 interaction can be targeted for the enhancement of TIL activation in lung tumors. Functional relevance is further supported by the analysis of a Siglec-9 polymorphism in cancer patients. This shows an association of hypomorphic alleles with the risk of developing squamous NSCLC. In addition, the same alleles were also associated with the risk for CRC. These polymorphisms were previously associated with an increased frequency of pulmonary emphysema, exacerbations of chronic obstructive pulmonary disease, and a hyperactive immune response of myeloid cells (33) . While the function of these polymorphisms needs to be tested in T cells, their linkage to disease outcome suggests a role for Siglec-9 in the development of lung and CRC. Our studies also show that the inhibitory Siglec-E receptor, the functional paralog of Siglec-9 and Sia-SAMPs in the tumor, influences the T cell-mediated immune response to tumors in mouse models. Reduction of Sia-SAMPs by using GNE-KO tumor cell lines led to a reduced growth of tumors. In particular, the use of the more antigenic cell line EMT6-HER2 showed rejection of the tumors in some mice when hyposialylated GNE-KO tumor cells were used. The KO of GNE in those cell lines most likely induces additional changes in glycosylation besides reducing the level of sialylation. An upregulation of polylactosamine could change the interaction with other immune-modulatory lectins, such as galectins (44) . Also, during the growth of tumors in mice, the cells could potentially acquire sialic acids from the host. Nevertheless, we observed a relevant growth difference in 2 different models. Previous experiments with B16 melanoma cell lines have also shown similar results, although different approaches were used for the reduction of tumor sialylation (45) . Another analysis with hyposialylated methylcholanthrene-induced (MCA-induced) tumors has shown growth inhibition of subcutaneous tumors (46) . Overexpression of inhibitory Siglec-9 on CD4 + and CD8 + T cells led to increased tumor growth, which indicates a functional role of inhibitory Siglecs on T cells. Exchange of inhibitory Siglec-E with activating SigE16 (extracellular Siglec-E domain with transcellular activating human Siglec-16) showed T cell-dependent growth inhibition. In an adoptive transfer model, we demonstrated that Siglec-E on T cells is functionally involved, although the model we used, with OVA-specific OT-I T on myeloid cells and NK cells within the tumor (38, 39) . Further experiments are needed to understand the functional relevance of these immune-modulatory receptors, including Siglec-9 or PD-1, on cell types other than T cells. However, it is likely that CD8 + T cells continue to play central roles in cancer immunotherapy, and we define Siglec-9 on CD8 + TILs as a potential therapeutic target for cancer immunotherapy.
Further characterization of Sig9 + CD8 + TILs revealed that these cells coexpress several inhibitory receptors, including PD-1, TIM-3, Lag3, and others. Our analysis suggests that Sig9 + CD8
+ TILs are a subpopulation of CD8 + PD-1 hi TILs, which are often tumor-specific (40) . Coexpression of multiple inhibitory receptors on T cells and also PD-1 hi TILs was associated with an exhaustion phenotype in cancer, including in patients with NSCLC (27, 41) . Indeed, functional analysis of TILs from NSCLC patients showed a significantly reduced capacity to produce cytokines and chemokines (Figure 3) + TILs with this previously described tumor-specific TIL subpopulation that could be potentially reactivated by immunotherapy. Other studies have also shown that, not only exhausted TILs coexpress a high frequency of inhibitory receptors, but also activated TILs (42) . This could mean that the Sig9 + CD8
+ TILs are in a higher activation state that could potentially be uncovered by blocking these different inhibitory receptors (43) .
Our analysis also includes functional studies both in vitro with human tissue and in vivo in different mouse models to demonstrate the relevance of inhibitory Siglecs on TILs and their interactions with cancer-associated Sia-SAMPs. The previous studies have provided evidence that Sia-SAMP/Siglec interactions can inhibit immune cell activation in in vitro models (21) (22) (23) 25) . The use of bivalent anti-Siglec-9 antibodies (clones 191240 and E10-286) led to an inhibition of T cell activation, which might be due -. RNA was isolated and the library prepared by Microsynth AG. Next-generation sequencing of the library and data analysis were performed by Microsynth AG. Count data from RNA-seq samples were analyzed using the edgeR Bioconductor package in R. Filtered genes, expressed at more than 1 count per million (cpm) in at least 3 samples, were analyzed using the QLF functions with batch correction for patients. All genes were ranked according to their F statistics comparing Siglec-9-positive and -negative samples. A weighted gene set enrichment analysis (GSEA) was performed using this preranked list using the GSEA java application (http://www.broad.mit.edu/gsea/). Box plots comparing expression levels between Siglec-9-positive and -negative cells were performed in R using logarithmically transformed cpm values. All original microarray data were deposited in the NCBI's Gene Expression Omnibus database (GEO GSE115305).
GNE-deficient cells and in vitro tumor cell killing with CD3/EpCAM TCB or CD3/CD19 TCB. Human and murine GNE-deficient tumor cell lines were created using CRISPR/CAS9. Guide RNAs were designed online using e-crisp.org, synthesized by Microsynth AG, and cloned into the pX458 vector (Addgene). A549, HT-29, and RAMOS cell lines were bought from ATCC. After transient transfection in tumor cells, single-cell sorting and subsequent screening for cell-surface sialylation were performed. Multiple GNE-deficient clones were pooled in order to avoid clonal selection when comparing with WT cell lines.
GNE-deficient cell lines and cell lines were refed with 5 mM Neu5Ac for 24 hours. Coincubation with magnetically isolated CD8 + T cells from healthy donors or tumor samples in the presence of catumaxomab (anti-CD3/anti-EpCAM; Fresnius) or blinatumomab, (anti-CD3/anti-CD19; Amgen) was performed at a concentration of 10 ng/ml. Alternatively, the respective cell lines were stained with carboxyfluorescein succinimidyl ester (CSFE) (Sigma-Aldrich) and spiked into full-tumor digests obtained from primary NSCLC or CRC samples. Tumor cell killing was analyzed by FACS staining for cleaved caspase-3 and by staining with the LIVE/DEAD Viability/Cytotoxicity Kit (Thermo Fisher Scientific). Tumor cells were gated by size and expression of EpCAM or CD19, respectively, as well as by negative gating using CD3, CD8, and CD4.
Genetic mouse models for in vivo analysis of Siglec function on T cells. Siglec-9 transgenic mice were described previously (21) . Siglec-9 transgenic mice (B6.Cg-Tg[CAG-Siglec-9]1Avrk) were crossed with CD4-Cre mice (B6Tg[CD4-cre]1Cwi) to obtain a T cell-specific overexpression of inhibitory human Siglec-9 in the C57BL/6 background. Transgenic mice expressing SigE16 chimeric Siglec-E with transmembrane and intracellular domain of activating human Siglec-16 (B6.Cg-Siglece < tm4E16Avrk>) were also described previously (18) . Tumor cell lines were injected into 8-to 12-week-old female mice, and tumor growth was monitored as described above.
SigE16 was crossed into OT-I transgenic mice. For the adoptive transfer of OVA-specific OT-I cells from WT or SigE16 mice, T cells were harvested from splenocytes and injected into WT C57BL/6 mice bearing subcutaneous MC38-OVA tumors. T cells were followed for proliferation by labeling with Cell Trace Violet (CTV) (Thermo Fishcells, has certain limitations and OVA is not directly comparable to naturally occurring tumor antigens.
Cancer immunotherapy and, in particular, checkpoint blockade with inhibitors of the PD-1/PD-L1/L2 axis and CTLA-4 are now routinely used in daily oncological practice (1, 47) . However, only a minority of cancer patients show objective responses under checkpoint blockade and only a few develop long-term remissions. Thus, combination therapies are a promising approach to improving response rates of immunotherapies and outcomes for patients (48, 49) . Our data suggest that targeting the Sia-SAMP/Siglec-9 pathway could improve antitumor immunity and define this pathway as an inhibitory immune checkpoint for T cell activation.
Methods
Patients and sample preparation. Surgical specimens were mechanically dissociated, digested with accutase (PAA Laboratories), collagenase IV (Worthington), hyaluronidase (MilliporeSigma), and DNAse type I (MilliporeSigma), filtered, washed, and frozen for future use. Singlecell suspensions were prepared. Human PBMCs were isolated by density gradient centrifugation using Histopaque-1077 (MilliporeSigma) from buffy coats obtained from healthy blood donors (Blood Bank, University Hospital Basel). Single-cell suspensions and PBMCs were frozen for later use in liquid nitrogen.
Multicolor flow cytometry. For multicolor flow cytometry, dead cells were stained using LIVE/DEAD Fixable Blue Dye (Invitrogen) and various panels of antibodies. Doublets were excluded in all analyses. Corresponding isotype antibodies or fluorescence-minus-one (FMO) samples were used as a control, in particular for the Siglec staining. All tumor samples were analyzed with a Fortessa LSR II Flow Cytometer (BD Biosciences). For infiltration analysis, mice were euthanized and tumors were mechanically dissociated and digested as described for the human sample preparation.
Staining for Siglec-7 and Siglec-9 ligands on tumor microarray. Tissue microarrays from US Biomax were used for screening of Siglec-9 ligand expression in lung cancer samples. For immunofluorescence staining, recombinant human Siglec-hFcs (R&D Systems) were mixed with PE-conjugated anti-human IgG (Jackson ImmunoResearch Laboratories) for 1 hour at 4°C prior to use. For the specific visualization of cancer cells, Anti-Multi-Cytokeratin (Leica Biosystems) staining was performed and visualized with a goat anti-mouse IgG coupled to Alexa Fluor 488 (Life Technologies). The general fluorescence per sample was measured in a ScanRI Microarray Scanner (PerkinElmer) and processed with ImageJ software, version 1.48 (NIH). Pictures were taken using a fluorescence microscope with original magnification of ×400 (Zeiss). Fluorescence was quantified using ImageJ software and normalized to background staining (secondary antibody only).
In vitro T cell activation and inhibition. Murine and human T cells were polyclonally stimulated with anti-CD3 and anti-CD28 antibodies (BioLegend). Anti-CD3 antibodies (0.5 μg/ml) were either coated overnight at 4°C for human T cells or added for mouse T cells. Anti-CD28 was added at 1 μg/ml. For inhibition assays with sialylated LGALS3BP, LGALS3BP was coated overnight as well. Activation of T cells was determined by staining for activation and proliferation markers by flow cytometry or measuring cytokines in supernatants by ELISA. For the SEB assay, primary NSCLC samples were incubated at 200,000 cells/well with SEB (10 ng/ml, MilliporeSigma) for 48 hours in the presence of full-length or digested Fab fragments of the 191240 er Scientific). Tumor growth was measured, and cell numbers were determined by counting beads and flow cytometry.
Association study of Siglec-9 polymorphism. The association analysis of Siglec-9 polymorphisms in lung cancer was studied on the TRILC cohort (34) . In total, 11,348 patients with lung cancer and 15,861 controls were studied for the rs2075803 and the rs2258983 SNPs. An association test was performed after adjusting for age, sex, and top principal components. Then we conducted a fixed effects meta-analysis with an inverse variance-weighted average method to combine the summary data from each association test. Meta-analysis was performed using SAS version 9.4 (SAS Institute Inc.). For the analysis of an association of Siglec-9 polymorphisms with the risk of CRC, SNP genotypes for rs2075803 and rs2258983 among cases and controls from imputed genotype data derived from samples genotyped on the Oncoarray platform and USC Norris Cancer Center were used. Using contingency table analysis (Fisher's test), we calculated odds ratios (OR), 95% CIs, and P values using an additive model and genotype-specific OR.
For additional information, see Supplemental Methods. Statistics. Statistical significance between 2 groups was determined using 2-tailed Student's t tests. Significance among more than 2 conditions was assessed using 1-way ANOVAs with multiple comparisons. For survival curve analysis, 2-way ANOVA was used. Survival analysis was performed by the Gehan-Breslow-Wilcoxon test, and multivariate analysis was done by Cox proportional hazard analysis. P < 0.05 was considered statistically significant.
Study approval. The local ethical committee in Basel, Switzerland, approved the sample collection and the use of clinical data (Ethikkomission Nordwest-und Zentralschweiz, EK321/10 and UBE
